ATE528648T1 - Verfahren zum nachweis antikörper-herstellender zellen - Google Patents

Verfahren zum nachweis antikörper-herstellender zellen

Info

Publication number
ATE528648T1
ATE528648T1 AT03778577T AT03778577T ATE528648T1 AT E528648 T1 ATE528648 T1 AT E528648T1 AT 03778577 T AT03778577 T AT 03778577T AT 03778577 T AT03778577 T AT 03778577T AT E528648 T1 ATE528648 T1 AT E528648T1
Authority
AT
Austria
Prior art keywords
antibody
producing
producing cells
antibody producing
cells
Prior art date
Application number
AT03778577T
Other languages
English (en)
Inventor
Derek Thomas Brown
Lisa Butler
Karen Dorothy Cromie
Meryn Ruth Griffiths
Alastair D G Lawson
Daniel John Lightwood
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0228188A external-priority patent/GB0228188D0/en
Priority claimed from GB0319587A external-priority patent/GB0319587D0/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE528648T1 publication Critical patent/ATE528648T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03778577T 2002-12-03 2003-12-01 Verfahren zum nachweis antikörper-herstellender zellen ATE528648T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0228188A GB0228188D0 (en) 2002-12-03 2002-12-03 Biological products
GB0319587A GB0319587D0 (en) 2003-08-20 2003-08-20 Biological products
PCT/GB2003/005254 WO2004051268A1 (en) 2002-12-03 2003-12-01 Assay for identifying antibody producing cells

Publications (1)

Publication Number Publication Date
ATE528648T1 true ATE528648T1 (de) 2011-10-15

Family

ID=32472152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03778577T ATE528648T1 (de) 2002-12-03 2003-12-01 Verfahren zum nachweis antikörper-herstellender zellen

Country Status (9)

Country Link
US (1) US7993864B2 (de)
EP (1) EP1570267B1 (de)
JP (1) JP4603894B2 (de)
AT (1) ATE528648T1 (de)
AU (1) AU2003285578B2 (de)
CA (1) CA2507004A1 (de)
ES (1) ES2374068T3 (de)
PT (1) PT1570267E (de)
WO (1) WO2004051268A1 (de)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658498A1 (de) 2003-08-20 2006-05-24 Celltech R & D Limited Verfahren zur gewinnung von antikörpern
ES2385829T3 (es) * 2003-08-20 2012-08-01 Ucb Pharma, S.A. Métodos para obtener anticuerpos
JP5102028B2 (ja) 2004-07-26 2012-12-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｃｄ１５４抗体
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
CA2655511C (en) * 2005-07-01 2017-03-21 John Schrader Methods of isolating cells and generating monoclonal antibodies
ES2382879T3 (es) 2005-09-14 2012-06-14 Ucb Pharma, S.A. Conjugado de anticuerpo - polímero de peine.
NZ569234A (en) 2005-12-09 2011-07-29 Ucb Pharma Sa Antibody molecules having specificity for human IL-6
JP5283219B2 (ja) * 2006-04-20 2013-09-04 学校法人自治医科大学 ベクター産生型腫瘍標的細胞
NZ572807A (en) 2006-05-19 2011-10-28 Alder Biopharmaceuticals Inc Culture method for obtaining a clonal population of antigen-specific b cells
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2514767A1 (de) 2006-12-19 2012-10-24 Ablynx N.V. Gegen Metalloproteinase der ADAM-Familie gerichtete Aminosäuren und Polypeptide damit zur Behandlung von Erkrankungen und Störungen im Zusammenhang mit ADAM
WO2012130874A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
DK2457928T3 (en) * 2007-03-13 2017-08-28 Univ Zuerich Monoclonal human tumor-specific antibody
EP2125894B1 (de) 2007-03-22 2018-12-19 Biogen MA Inc. Bindungsproteine mit antikörpern, antikörperderivaten und antikörperfragmenten mit spezifischer bindung an cd154 sowie ihre verwendung
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
GB0721752D0 (en) * 2007-11-06 2007-12-19 Univ Southampton Configurable electronic device and method
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
CA2720763A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
JP6034023B2 (ja) 2008-05-16 2016-11-30 アブリンクス エン．ヴェー． Ｃｘｃｒ４及び他のｇｐｃｒに指向性を有するアミノ酸配列及びそれを含む化合物
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
CA2747644C (en) 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
BRPI1008692B8 (pt) 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
CA2744103C (en) * 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
ES2700442T3 (es) 2009-02-25 2019-02-15 Ucb Biopharma Sprl Método para producir anticuerpos
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
SI2993231T1 (sl) 2009-09-24 2018-10-30 Ucb Biopharma Sprl Bakterijski sev za izražanje rekombinantnega proteina, ki ima proteazno deficientno DEGP-zadrževalno šaperonsko aktivnost, ter onesposobljena gena TSP in PTR
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011043077A1 (ja) * 2009-10-09 2011-04-14 川崎重工業株式会社 未分化多能性幹細胞の識別方法及び装置並びに自動培養方法及び装置
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US8734798B2 (en) 2009-10-27 2014-05-27 Ucb Pharma S.A. Function modifying NAv 1.7 antibodies
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
EP2506874A1 (de) 2009-12-01 2012-10-10 Ablynx N.V. Von-willebrand-faktor-spezifische bindemittel und ihre verwendung
EP3309176B1 (de) 2009-12-14 2025-10-01 Ablynx N.V. Variable einzeldomänen-antikörper gegen ox40l, konstrukte und ihre therapeutische verwendung
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
US9625464B2 (en) 2010-03-25 2017-04-18 National University Corporation University Of Toyama Fluorescent probe for plasma cell identification and isolation, and plasma cell identification or isolation method using the probe
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
WO2012062713A1 (en) 2010-11-08 2012-05-18 Novartis Ag Cxcr2 binding polypeptides
ES2632583T3 (es) 2011-01-14 2017-09-14 Ucb Biopharma Sprl Anticuerpo que se une a IL-17A e IL-17F
US9487583B2 (en) 2011-03-30 2016-11-08 National University Corporation University Of Toyama Method for selecting plasma cells or plasmablasts, method for producing target antigen specific antibodies, and novel monoclonal antibodies
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
EP4350345A3 (de) 2011-06-23 2024-07-24 Ablynx N.V. Verfahren zur vorhersage, erkennung und reduzierung von aspezifischer proteininterferenz in tests mit variablen immunglobulin-einzeldomänen
EP2974737B1 (de) 2011-06-23 2025-10-22 Ablynx N.V. Verfahren für vorhersage, nachweis und verringerung von aspezifischer proteininterferenz bei tests mit variablen immunglobulin-einzeldomänen
WO2013007388A1 (en) 2011-07-13 2013-01-17 Ucb Pharma, S.A. Bacterial host strain expressing recombinant dsbc
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
PT2758432T (pt) 2011-09-16 2019-06-14 Ucb Biopharma Sprl Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
MX351502B (es) 2011-11-11 2017-10-18 Ucb Pharma Sa Anticuerpos de union de albumina y fragmentos de union de los mismos.
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
US8921055B2 (en) 2012-10-30 2014-12-30 Berkeley Lights, Inc. Detecting cells secreting a protein of interest
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
EP3831398A1 (de) 2013-10-25 2021-06-09 PsiOxus Therapeutics Limited Onkolytische adenoviren, die mit heterologen genen ausgestattet sind
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
BR112017023158A2 (pt) 2015-04-30 2018-07-24 Harvard College anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CN107660152B (zh) 2015-05-27 2021-11-05 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
MY206805A (en) 2015-10-27 2025-01-08 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
EP3378488A4 (de) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur verbesserung der humoralen immunreaktion
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
US10222373B2 (en) 2016-02-29 2019-03-05 Rarecyte, Inc. Method to identify antigen-specific immune cells
US9442113B1 (en) 2016-02-29 2016-09-13 Rarecyte, Inc. Method to identify antigen-specific immune cells for therapeutic development
US9395367B1 (en) 2016-02-29 2016-07-19 Rarecyte, Inc. Method to identify antigen-specific B cells for antibody development
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2017214376A1 (en) 2016-06-10 2017-12-14 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
SG11201901597UA (en) 2016-08-26 2019-03-28 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CN112236451A (zh) * 2017-10-26 2021-01-15 Essenlix公司 引起性传播疾病的细菌和免疫t细胞检测
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
EP3806898B1 (de) 2018-06-18 2025-10-08 UCB Biopharma SRL Gremlin-1-antagonist zur verwendung in der behandlung von krebs
EP3866933A1 (de) 2018-10-16 2021-08-25 UCB Biopharma SRL Verfahren zur behandlung von myasthenia gravis
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
JP7410143B2 (ja) 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
KR102800844B1 (ko) 2019-02-18 2025-04-29 가부시키가이샤 에누비 켄코우겡큐쇼 세포의 선발 방법, 핵산의 제조 방법, 재조합 세포의 제조 방법, 목적 물질의 제조 방법, 의약 조성물의 제조 방법, 및 시약
TWI884171B (zh) 2019-09-30 2025-05-21 日商東京應化工業股份有限公司 分泌物產生細胞的篩選方法、及分泌物產生細胞的篩選套組
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
US20230151109A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9
WO2021160267A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4103611B1 (de) 2020-02-13 2024-03-27 UCB Biopharma SRL Bispezifische, an hvem und cd9 bindende antikörper
US20230151108A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
EP4103610A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Anti-cd4-ctla4 bispezifische antikörper
CN116348494A (zh) 2020-10-13 2023-06-27 阿尔米雷尔有限公司 双特异性分子和使用其的治疗方法
IL301859A (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules that multimerise cd45
WO2022089767A1 (en) 2020-11-02 2022-05-05 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
IL303294A (en) 2020-12-07 2023-07-01 UCB Biopharma SRL Antibodies against interleukin-22
AU2021395729A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
TW202241968A (zh) 2021-04-22 2022-11-01 大陸商廣東菲鵬制藥股份有限公司 雙特異性多功能融合多肽
CA3218933A1 (en) 2021-05-03 2022-11-10 UCB Biopharma SRL Antibodies
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
AU2023400451A1 (en) 2022-11-28 2025-05-22 UCB Biopharma SRL Treatment of fibromyalgia
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies
WO2025158009A1 (en) 2024-01-26 2025-07-31 Almirall S.A. Bispecific molecules and methods of treatment using the same
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) * 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0286405A3 (de) 1987-04-08 1989-08-09 Synbiotics Corporation Verfahren zur frühen Auswahl von inneren Bildern der Anti-idiotyp-Antikörper
US5264341A (en) * 1989-08-30 1993-11-23 Eli Lilly And Company Selective cloning for high monoclonal antibody secreting hybridomas
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5256542A (en) 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DE69332884T2 (de) 1992-10-21 2003-11-20 Stefan Miltenyi Direkte auswahl von zellen durch ein aussheidungsprodukt
AU770540B2 (en) 1998-04-30 2004-02-26 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel method for the identification of clones conferring a desired biological property from an expression library
DK1078263T3 (da) 1998-05-11 2009-11-02 Miltenyi Biotec Gmbh Fremgangsmåde til direkte selektion af antigen-specifikke T-celler
JP2000304750A (ja) * 1999-04-16 2000-11-02 Fuji Photo Film Co Ltd 発光標識イムノアッセイ及びその分析要素
ES2263583T3 (es) * 2000-01-31 2006-12-16 Emory University Sistema y procedimiento de analisis inmunitario.
AUPR177400A0 (en) 2000-11-29 2000-12-21 Cancerprobe Pty Ltd Probes for identifying cancer-specific antigens
GB0118337D0 (en) * 2001-07-27 2001-09-19 Lonza Biologics Plc Method for selecting antibody expressing cells
US20040240687A1 (en) * 2003-05-30 2004-12-02 Graetz Michael L. Flat panel speaker
GB0412973D0 (en) 2004-06-10 2004-07-14 Celltech R&D Ltd Identification of antibody producing cells

Also Published As

Publication number Publication date
US7993864B2 (en) 2011-08-09
US20060148012A1 (en) 2006-07-06
JP4603894B2 (ja) 2010-12-22
EP1570267A1 (de) 2005-09-07
CA2507004A1 (en) 2004-06-17
AU2003285578B2 (en) 2010-07-15
AU2003285578A1 (en) 2004-06-23
ES2374068T3 (es) 2012-02-13
PT1570267E (pt) 2012-01-03
JP2006509217A (ja) 2006-03-16
EP1570267B1 (de) 2011-10-12
WO2004051268A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
ATE528648T1 (de) Verfahren zum nachweis antikörper-herstellender zellen
EA200971114A1 (ru) Определение антигенов, расположенных на эритроцитах, и антиэритроцитарных антител
DE60141844D1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
NO20076662L (no) Deteksjon av et malantigen uavhengig av tilstedevaerelse eller fravaer av et korresponderende terapeutisk antistoff
DK1322960T4 (da) Allergen-mikroarrayassay
MX2007014815A (es) Metodos de inmunoanalisis mejorados.
EA200500643A1 (ru) Способ неконкурентного иммуноанализа для определения малых аналитов
DE60307645D1 (de) Hoch-durchsatz assay zur messung von zellulären antworten mit hilfe von mikroarrays
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
AR018821A1 (es) Procedimiento para la determinacion de antibioticos con nucleo beta-lactama en un liquido biologico
CN107367616A (zh) 一种前列腺特异性抗原检测试剂与试剂盒
SE0001670D0 (sv) Mass-spectrometry-based biosensor
DK0755517T3 (da) Fremgangsmåde til detektion af tilstedeværelse af en Mycobacterium-art og et kit og antistoffer til anvendelse i denne
SG164389A1 (en) Detection of a therapeutic antibody in an experimental animal
EP2023139A4 (de) Immuntestverfahren und -chip
DE602006018432D1 (de) Antigennachweis
NO20052553L (no) Cobalaminanalyse.
ATE533053T1 (de) Nicht-elispot-test
WO2004023146A3 (en) Methods for assaying protein-protein interactions
DK1879029T3 (da) Immuneftervisningskit i forbindelse med neuroglobinenzym samt anvendelse heraf
DK1192469T3 (da) Assay
Kergaravat et al. Magneto immunofluorescence assay for diagnosis of celiac disease
KR20170010526A (ko) 암 진단용 elisa 키트 및 그를 이용한 암 진단 방법
RU2007140911A (ru) Способ выявления антигенов и антител в иммуноферментном анализе
ATE440968T1 (de) Verfahren zur diagnostizierung von aspirinunverträglichkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties